CDC advises healthcare providers on new tools to combat RSV

In a recent public health advisory, the United States Centers for Disease Control and Prevention (CDC) predicts the respiratory syncytial virus (RSV) activity for the upcoming winter season and encourages clinicians to adopt and implement new RSV prevention tools. 

dvisory: Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients, Distributed via the CDC Health Alert Network, September 05, 2023, 2:00 PM ET CDCHAN-00498. Image Credit: Pete Hansen / Shutterstock.com Advisory: Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients, Distributed via the CDC Health Alert Network, September 05, 2023, 2:00 PM ET CDCHAN-00498. Image Credit: Pete Hansen / Shutterstock.com

Background

Every year, the CDC issues a health advisory for the public and clinicians throughout the United States through its Health Alert Network (HAN) regarding RSV activity. RSV, a ribonucleic acid (RNA) virus, causes severe respiratory infections in infants, children, and older adults.

Prior to the coronavirus disease 2019 (COVID-19) pandemic, the annual RSV season in the U.S. began in the fall and often reached its peak by winter. Due to mitigation measures implemented during the pandemic, RSV spread reduced between May 2020 and March 2021; however, the spread of RSV eventually returned to its typical seasonal trend. 

However, in 2021, RSV began spreading in May, peaked by August, and continued through December. In 2022, RSV again became active in the summer but peaked in October and November, declining rapidly by winter. 

Unlike its onset timing, post-pandemic RSV activity follows the same geographic pattern as before the pandemic in 2021-2022. More specifically, RSV often begins to spread in Florida, moving throughout the southeast and then spreading further to the northern and western U.S.

In 2023, the CDC observed increased RSV activity in the southeastern U.S. in late August. According to the National Respiratory and Enteric Virus Surveillance System (NREVSS) data, the weekly percentage of polymerase chain reaction (PCR) test-based positive detections remained below the season's onset threshold of 3% for two weeks. 

In Georgia, rates of RSV-associated hospitalizations increased, whereas in Florida, the three-week PCR positivity moving average was over 5% from the week ending July 22, 2023. 

New tools for RSV prevention

In 2023, nirsevimab, as well as RSVPreF3 and RSVpreF vaccines, became available to the public since their recent approval. Nirsevimab is a U.S. Food and Drug Administration (FDA) approved long-acting monoclonal antibody (mAb) that is currently indicated for infants younger than eight months, as well as children between eight to 19 months of age who are at a high risk of severe illness due to RSV infection. Clinical trials have established that a single intramuscular injection of nirsevimab is safe, effective, and could protect infants for at least five months.

The CDC asked clinicians to consult local, territorial, or state authorities on the timing of nirsevimab use, especially in regions with less predictable RSV seasonality. Current recommendations for nirsevimab include one dose for all infants ages eight months or younger entering their first RSV season or born during this time, within the first week of birth, and another as early as possible during their first RSV season. The prescribed dose is 50 and 100 mg for infants weighing less than five kilograms (kg) and over five] kg, respectively. 

The CDC also recommends that children between eight and 19 months of age who are at an increased risk of RSV infection, such as those who are immunocompromised, should receive one dose of 200 mg nirsevimab before entering their second RSV season. 

According to the American Academy of Pediatrics (AAP) recommendations, children 24 months or younger at a higher risk for severe RSV disease could also receive palivizumab mAb until nirsevimab becomes available.

RSVPreF3 and RSVpreF, which are recombinant protein vaccines, have also received FDA approval for use in adults 60 years and older. In a clinical trial that included 38,177 participants over 60 years of age, these vaccines were associated with over 80% efficacy in preventing RSV-related lower respiratory tract disease. The RSVpreF vaccine was also approved for use in pregnant women between 32-36 weeks.

Clinicians are advised to discuss RSV vaccination with their adult patients who are over 60 years of age. Notably, all vaccines for which a patient is eligible, including those against COVID-19, influenza, and RSV, may be administered together.

Adults with advanced age and specific chronic medical conditions, such as chronic obstructive pulmonary disease (COPD), might benefit the most from vaccination. Clinicians should also consider testing symptomatic patients to inform patient management and ask those testing positive to stay home to prevent onward viral transmission.

Conclusions

RSV causes between 58,000-80,000 and 60,000-160,000 hospitalizations in children five years and younger and adults aged 65 years and older, respectively, every year in the U.S.

Given its increased activity in the southeastern U.S. in August 2023, healthcare service providers must remain prepared and informed and take preventive measures to reduce the risk of RSV-related hospitalizations and death.

Source:
  • Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients, Distributed via the CDC Health Alert Network, September 05, 2023, 2:00 PM ET CDCHAN-00498. https://emergency.cdc.gov/han/2023/han00498.asp
Neha Mathur

Written by

Neha Mathur

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mathur, Neha. (2023, September 10). CDC advises healthcare providers on new tools to combat RSV. News-Medical. Retrieved on July 13, 2024 from https://www.news-medical.net/news/20230910/CDC-advises-healthcare-providers-on-new-tools-to-combat-RSV.aspx.

  • MLA

    Mathur, Neha. "CDC advises healthcare providers on new tools to combat RSV". News-Medical. 13 July 2024. <https://www.news-medical.net/news/20230910/CDC-advises-healthcare-providers-on-new-tools-to-combat-RSV.aspx>.

  • Chicago

    Mathur, Neha. "CDC advises healthcare providers on new tools to combat RSV". News-Medical. https://www.news-medical.net/news/20230910/CDC-advises-healthcare-providers-on-new-tools-to-combat-RSV.aspx. (accessed July 13, 2024).

  • Harvard

    Mathur, Neha. 2023. CDC advises healthcare providers on new tools to combat RSV. News-Medical, viewed 13 July 2024, https://www.news-medical.net/news/20230910/CDC-advises-healthcare-providers-on-new-tools-to-combat-RSV.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Using design thinking to create autism-inclusive healthcare environments